

# Elias Karl Mai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5375504/publications.pdf>

Version: 2024-02-01

45  
papers

891  
citations

623188

14  
h-index

500791

28  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1818  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. <i>Haematologica</i> , 2022, 107, 1891-1901.	1.7	15
2	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.	0.8	115
3	Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. <i>Leukemia</i> , 2021, 35, 809-822.	3.3	7
4	Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. <i>Immunotherapy</i> , 2021, 13, 143-154.	1.0	9
5	Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 1.	2.8	57
6	Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. <i>Leukemia</i> , 2021, 35, 3007-3011.	3.3	4
7	Submyeloablative total body irradiation-based conditioning and allogeneic stem cell transplantation in high-risk myeloma with early progression after up-front autologous transplantation. <i>British Journal of Haematology</i> , 2021, , .	1.2	1
8	Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. <i>Cancers</i> , 2021, 13, 4856.	1.7	3
9	Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network. <i>Blood</i> , 2021, 138, 3792-3792.	0.6	0
10	Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial. <i>Blood</i> , 2021, 138, 486-486.	0.6	25
11	Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial. <i>Blood</i> , 2021, 138, 463-463.	0.6	19
12	Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma. <i>Leukemia</i> , 2020, 34, 1192-1196.	3.3	26
13	Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2020, 26, 5879-5886.	3.2	3
14	Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. <i>Leukemia</i> , 2020, 34, 1853-1865.	3.3	47
15	Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 14-14.	0.6	0
16	Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. <i>Leukemia</i> , 2019, 33, 258-261.	3.3	5
17	Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e43.	0.2	0
18	Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 71.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial. <i>Blood Cancer Journal</i> , 2019, 9, 45.	2.8	7
20	Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e208.	0.2	0
21	Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up. <i>Blood</i> , 2019, 134, 3308-3308.	0.6	3
22	Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels. <i>Haematologica</i> , 2018, 103, e162-e164.	1.7	5
23	A systematic classification of death causes in multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 30.	2.8	26
24	Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. <i>Cancer Medicine</i> , 2018, 7, 307-316.	1.3	42
25	Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial. <i>Blood</i> , 2018, 132, 2003-2003.	0.6	3
26	Potential therapeutic targets in plasma cell disorders: A flow cytometry study. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 145-152.	0.7	13
27	Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. <i>Haematologica</i> , 2017, 102, 1432-1438.	1.7	14
28	Response After Induction Therapy in Transplant-eligible Newly-diagnosed Myeloma - a Pooled Analysis from Three Subsequent Multicenter Phase III Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e76.	0.2	0
29	Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. <i>British Journal of Haematology</i> , 2016, 173, 731-741.	1.2	50
30	Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. <i>Haematologica</i> , 2016, 101, e485-e487.	1.7	14
31	Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. <i>Blood</i> , 2016, 128, 1226-1233.	0.6	185
32	Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. <i>American Journal of Hematology</i> , 2016, 91, E473-E477.	2.0	27
33	Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries. <i>Scientific Reports</i> , 2016, 6, 22084.	1.6	15
34	Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApSE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. <i>BMC Cancer</i> , 2016, 16, 290.	1.1	5
35	Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. <i>European Radiology</i> , 2016, 26, 3939-3948.	2.3	27
36	Abstract 2283: Molecular signaling in multiple myeloma: association of RAS/RAF mutation status and MAPK pathway activation in primary myeloma patient biopsies. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
37	Analysis of Long-Term Survival in Multiple Myeloma Patients after First-Line Autologous Stem Cell Transplantation: Impact of Clinical Risk Factors and Duration of Response. <i>Blood</i> , 2016, 128, 4649-4649.	0.6	0
38	A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. <i>Haematologica</i> , 2015, 100, 818-825.	1.7	45
39	Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. <i>Haematologica</i> , 2015, 100, 964-969.	1.7	62
40	Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 4233-4233.	0.6	2
41	Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways. <i>Blood</i> , 2015, 126, 723-723.	0.6	0
42	Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4. <i>Blood</i> , 2015, 126, 3187-3187.	0.6	0
43	Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial. <i>Blood</i> , 2014, 124, 3475-3475.	0.6	1
44	Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG. <i>Blood</i> , 2014, 124, 4777-4777.	0.6	0
45	The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2